We are international
Donate
• IMF TV TEXT SIZE   
#Ask Dr. Durie

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
    next      view all

03.26.15   Does the type of myeloma impact the choice of treatment?

In this week’s episode of #AskDrDurie, IMF Chairman Dr. Brian Durie looks at the factors of myeloma that affect the choice of treatment, including the type of myeloma and any chromosome abnormalities, as well as genetic testing done on the patient.


03.19.15   Dr. Durie, what is your perspective on the discussion about the cost of cancer drugs?

IMF Chairman Dr. Brian Durie weighed in on the high cost of cancer drugs after the recent article in Mayo Clinic Proceedings. He discusses what needs to be done within the healthcare system to better serve the patients.


03.05.15   What is the recommended use of Biaxin in patients with myeloma?

In this episode of the IMF's weekly web series, #AskDrDurie, IMF Chairman Dr. Brian Durie discusses his recommendation for use of the antibiotic Biaxin for patients with myeloma.


02.26.15   What is the typical speed of improvement in the Freelite and protein levels with myeloma treatment?

In this new episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses how fast a myeloma patient would see improvement in both Freelite and protein levels with treatment such as three-drug combinations.


02.19.15   What are some treatment options for the t(4;14) abnormality?

In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses treatment options available for those myeloma patients with the t(4;14) abnormality, including IMiDs, next-generation proteasome inhibitors, novel combination therapies, and autologous stem cell transplants.


02.12.15   What does ‘dysplasia’ mean within the bone marrow report?

In this episode of the IMF’s weekly web series, #AskDrDurie, IMF Chairman Dr. Brian Durie explains what dysplasia means when it shows up on a bone marrow report.


02.05.15   Should gadolinium be used as part of MRI testing?

In this episode of #AskDrDurie, IMF Chairman Dr. Brian Durie discusses the use of gadolinium in MRI testing, specifically for patients with abnormal kidney function.


01.29.15   What is the M protein?

This week, Dr. Brian Durie of the IMF answers a patient's question about the M protein and how levels are affected by time and treatment.


01.22.15   If bone density is low, does that mean myeloma is present?

In this week's episode of #AskDrDurie, IMF Chairman Dr. Brian Durie answers a patient's question about levels of bone density and how they connect to myeloma.


01.15.15   What is the 17p deletion?

In this week’s episode of #AskDrDurie Dr. Brian Durie discusses the importance of the 17p deletion chromosome abnormality when remission has been achieved.


    next      view all